CSL Behring Discontinues Production and Distribution of Monoclate-P®
Tuesday, March 20, 2018
VIA The National Hemophilia Foundation:
CSL Behring has announced that due to patients transitioning from plasma-derived to recombinant products, it has been difficult to sustain the production and distribution of Antihemophilic Factor Monoclate-P® Factor VIII:C Pasteurized Monoclonal Antibody Purified. Therefore production of Monoclate-P® will be discontinued, and CSL Behring estimates that existing supplies will only be available until December 2018.
If you are currently using Monoclate-P®, please contact your physician or hemophilia treatment center to learn about other options that are available to you for treatment.
Alnylam Suspends Fitusiran Dosing due to Thrombotic Event
Thursday, September 7, 2017
VIA The Hemophilia Federation of America: Alnylam recently became aware of a fatal serious adverse event (SAE) that occurred in a patient with hemophilia A who was receiving fitusiran in the Phase 2 OLE study. As a result, the Company has suspended dosing in all ongoing fitusiran studies pending further review of the safety event and development of a risk mitigation strategy.
Click here for Alnylam’s full press release link is: Press Release